Arnaud Flamand

Arnaud advises local and international (public and privately held) companies, investment banks and institutions, and private equity funds on all aspects related to corporate finance, with a focus on M&A, capital markets, private equity and funds structuring.

Arnaud has advised clients in a wide range of M&A and capital markets operations. Arnaud has also advised clients on the incorporation of alternative investment funds under the form of partnerships, structuration of all internal documentation and further capital calls and raising (including equalisations).

• Advised MDxHealth on its initial public offering on the Nasdaq. 
• Advised Mayfair Equity Partners on the acquisition of the Jonckers Group.
• Advised Mithra Pharmaceuticals on the offering of its EUR 125 million senior unsecured convertible bonds.
• Advised Mithra Pharmaceuticals on the conclusion of a EUR 100 million equity financing agreement (under ISDA rules) with Goldman Sachs International.
• Advised Mithra Pharmaceuticals on the conclusion of a senior secured convertible facilities agreement with Highbridge and Whitebox in an amount of up to EUR 100 million.
• Advised a European group on the acquisition of a non-listed Belgian company active in the food industry.
• Advised a Belgian group on the acquisition and restructuring of a large retail-shopping group.
• Advised the syndicate of banks acting on Nyxoah's initial public offering on Euronext Brussels.
• Advised a European group on the acquisition of two Belgian companies active in the food industry.